{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:36:29Z","timestamp":1772228189328,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1124\/dmd.109.028712","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T02:09:24Z","timestamp":1260410964000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Glucuronidation of Dihydrotestosterone and trans-Androsterone by Recombinant UDP-Glucuronosyltransferase (UGT) 1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites"],"prefix":"10.1016","volume":"38","author":[{"given":"Jin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory P.","family":"Remmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.028712_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.105.015891","article-title":"Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue","volume":"69","author":"Chouinard","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib2","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1074\/jbc.M707630200","article-title":"CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds","volume":"283","author":"Collom","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.028712_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0090-9556(24)15100-8","article-title":"In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin","volume":"28","author":"Fisher","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/dmd.107.018705","article-title":"Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates","volume":"36","author":"Fujiwara","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1124\/dmd.30.12.1512","article-title":"Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach","volume":"30","author":"Galetin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0090-9556(25)07355-6","article-title":"Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein","volume":"24","author":"Green","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.105.007658","article-title":"Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement","volume":"34","author":"Hallifax","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib8","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bcp.2007.11.008","article-title":"Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1\u03b1,25-dihydroxyvitamin D3 conjugation","volume":"75","author":"Hashizume","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib10","first-page":"1029","article-title":"Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model","volume":"29","author":"Hutzler","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2125.2009.03386.x","article-title":"In vitro and in vivo glucuronidation of midazolam in humans","volume":"67","author":"Hyland","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.107.018788","article-title":"Resveratrol (trans-resveratrol-3,5,4\u2032-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources","volume":"36","author":"Iwuchukwu","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.bcp.2004.02.014","article-title":"Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4","volume":"67","author":"Kaku","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib14","first-page":"1644","article-title":"Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism","volume":"29","author":"Kenworthy","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.109.028712_bib16","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1021\/bi9715627","article-title":"Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites","volume":"37","author":"Korzekwa","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.109.028712_bib17","first-page":"368","article-title":"Substrate inhibition kinetics for cytochrome P450-catalyzed reactions","volume":"29","author":"Lin","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib18","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1124\/dmd.105.004093","article-title":"Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases","volume":"33","author":"Luukkanen","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib19","doi-asserted-by":"crossref","first-page":"36205","DOI":"10.1074\/jbc.M807961200","article-title":"Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase","volume":"283","author":"Mackenzie","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.028712_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/bdd.418","article-title":"Effects of \u03b2-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9","volume":"25","author":"Mano","year":"2004","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.109.028712_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmb.2007.03.066","article-title":"Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7","volume":"369","author":"Miley","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1124\/dmd.109.028712_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.109.028712_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/dmd.107.019281","article-title":"Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties","volume":"36","author":"Ohno","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib25","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1074\/jbc.M609417200","article-title":"Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation","volume":"282","author":"Opera\u00f1a","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.028712_bib26","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/carcin\/bgi197","article-title":"Isoflavones modulate the glucuronidation of estradiol in human liver microsomes","volume":"26","author":"Pfeiffer","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.109.028712_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1081\/DMR-100101944","article-title":"Structural and functional studies of UDP-glucuronosyltransferases","volume":"31","author":"Radominska-Pandya","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.109.028712_bib28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/dmd.30.12.1364","article-title":"Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1","volume":"30","author":"Rios","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.107.019885","article-title":"The \u201calbumin effect\u201d and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-4615-0667-6_56","article-title":"Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site","volume":"500","author":"Schrag","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/dmd.109.028712_bib32","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems","author":"Segel","year":"1993"},{"key":"10.1124\/dmd.109.028712_bib33","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1074\/jbc.M008799200","article-title":"A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4","volume":"276","author":"Shou","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.028712_bib34","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/bi00187a009","article-title":"Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site","volume":"33","author":"Shou","year":"1994","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.109.028712_bib35","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr1539","article-title":"Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants","volume":"8","author":"Sun","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1124\/dmd.109.028712_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.109.028712_bib37","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1124\/mol.108.048645","article-title":"Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites","volume":"74","author":"Uchaipichat","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.028712_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028712_bib39","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1124\/dmd.30.11.1266","article-title":"Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624023043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624023043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.028712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:47:42Z","timestamp":1739897262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624023043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0090955624023043"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.028712","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucuronidation of Dihydrotestosterone and trans-Androsterone by Recombinant UDP-Glucuronosyltransferase (UGT) 1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.028712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}